Abbott Laboratories revenue
Abbott Laboratories's revenue was $44.33bn in fiscal 2025, up 5.7% on the year before. Since fiscal 2009 ($30.76bn) it has grown at a compound 2.3% a year. Over the last twelve months it was $46.59bn.
Revenue history
| Fiscal year | 2009Dec 2009 | 2010Dec 2010 | 2011Dec 2011 | 2012Dec 2012 | 2013Dec 2013 | 2014Dec 2014 | 2015Dec 2015 | 2016Dec 2016 | 2017Dec 2017 | 2018Dec 2018 | 2019Dec 2019 | 2020Dec 2020 | 2021Dec 2021 | 2022Dec 2022 | 2023Dec 2023 | 2024Dec 2024 | 2025Dec 2025 | LTMJun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 30.8 | 35.2 | 21.4 | 19.1 | 19.7 | 20.2 | 20.4 | 20.9 | 27.4 | 30.6 | 31.9 | 34.6 | 43.1 | 43.7 | 40.1 | 42.0 | 44.3 | 46.6 |
| Growth on the year before | — | +14.3% | −39.1% | −11.0% | +3.2% | +3.0% | +0.8% | +2.2% | +31.3% | +11.6% | +4.3% | +8.5% | +24.5% | +1.3% | −8.1% | +4.6% | +5.7% | — |
| Gross profit | — | — | — | — | — | — | — | 11.8 | 15.0 | 17.9 | 18.7 | 19.6 | 24.5 | 24.5 | 22.1 | 23.2 | 25.0 | 26.4 |
| Gross margin | — | — | — | — | — | — | — | 56.4% | 54.7% | 58.4% | 58.5% | 56.6% | 57.0% | 56.1% | 55.2% | 55.4% | 56.4% | 56.6% |
Where the revenue comes from
| Region | Revenue | Share | YoY |
|---|---|---|---|
| Outside the US | $27.2B | 61.4% | ▲ 6.1% |
| All Other Countries (part of Outside the US) | $16B | 58.7% | ▲ 8.1% |
| Germany (part of Outside the US) | $2.8B | 10.1% | ▲ 8.7% |
| China (part of Outside the US) | $1.9B | 7.0% | ▼ 9.7% |
| Switzerland (part of Outside the US) | $1.9B | 6.9% | ▲ 7.1% |
| India (part of Outside the US) | $1.9B | 6.9% | ▲ 3.0% |
| Japan (part of Outside the US) | $1.5B | 5.4% | ▲ 2.4% |
| United Kingdom (part of Outside the US) | $1.3B | 4.9% | ▲ 13.1% |
| United States | $17.1B | 38.6% | ▲ 4.9% |
From Abbott Laboratories's 10-K filed February 20, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.
Revenue against peers
| Company | Revenue | Growth | 3-year growth a year |
|---|---|---|---|
| Abbott Laboratories | $46.59bn | 8.1% | 5.0% |
| Medtronic | $37.54bn | 9.8% | 6.0% |
| Stryker Corporation | $26.30bn | 7.9% | 9.8% |
| GE HealthCare | $21.64bn | 6.9% | 3.9% |
| Boston Scientific | $21.07bn | 8.9% | 15.3% |
| Koninklijke Philips NV | $20.16bn | 3.4% | — |
Compare with peers
- Medtronic revenue
- Stryker Corporation revenue
- GE HealthCare revenue
- Boston Scientific revenue
- Koninklijke Philips NV revenue
Head to head: ABT vs MDTABT vs SYKABT vs GEHC
More: Health Care Equipment stocks compared, Health Care sector, rankings of US companies